0001562180-24-001624.txt : 20240222
0001562180-24-001624.hdr.sgml : 20240222
20240222170848
ACCESSION NUMBER: 0001562180-24-001624
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240220
FILED AS OF DATE: 20240222
DATE AS OF CHANGE: 20240222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Duker Jay S.
CENTRAL INDEX KEY: 0001630864
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 24666004
MAIL ADDRESS:
STREET 1: C/O ELEVEN BIOTHERAPEUTICS
STREET 2: 215 1ST ST. #400
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-02-20
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001630864
Duker Jay S.
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
true
true
false
false
President and CEO
false
Common Stock
2024-02-20
4
G
false
20000.00
0.00
D
31920.00
D
Common Stock
2024-02-20
4
G
false
20000.00
0.00
A
20000.00
I
Family Trust
On February 20, 2024, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust.
These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
/s/ Ron Honig, Attorney-in-Fact
2024-02-22